Metabolic-associated fatty liver disease clinical audit

Activity aim

In this clinical audit, you will conduct an assessment of patients who are at risk of metabolic associated fatty liver disease (MAFLD), calculate their risk of liver fibrosis using validated tools and decide on further management.

Why take part in this program?

• Evaluate the risk of liver fibrosis in 5 patients with MAFLD risk in line with latest evidence, and develop future management plans informed by best practice and guidelines.
• Earn 6 CPD hours upon completion.

Learning outcomes

• Assess patients who are at risk of metabolic associated fatty liver disease (MAFLD) and identify their risk factors.
• Calculate patients’ risk level of liver fibrosis using validated tools.
• Develop guidelines-based plans for patients’ ongoing management in primary care.
• Identify patients who should be referred to specialist care, and collect appropriate information for a quality referral.

Inclusion criteria

Patients who are eligible for this clinical audit:

• Are 35 years or older
• Have not already been referred to a hepatologist for management of MAFLD or other liver conditions
• Have any of the following risk factors for MAFLD:
  
  • Overweight or obesity
  • Type 2 diabetes
  • Metabolic syndrome
  • Abnormal liver blood tests
  • Hepatic steatosis

How long should it take?

The program has been designed to take approximately 4-6 weeks to complete. This includes patient recall from your practice, patient consult and program evaluation.

Tips to recruit patients

Recruitment may occur:

• Opportunistically as you review appropriate patients as part of usual care.
• By active recall.

This activity is part of the education that won the Excellence in Education category at the 2023 Australian life sciences industry PRIME awards for ThinkGP and the Liver Foundation.

This independent medical activity is sponsored by the Liver Foundation, supported by an unrestricted education grant from Novo Nordisk.